ArticleCardiovascular diabetology2026
Association between estimated glucose disposal rate and cause-specific mortality among individuals with metabolic dysfunction-associated steatotic liver disease.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Head-to-head comparison of fasting-insulin-based versus non-insulin-based insulin resistance surrogates for predicting all-cause and cardiovascular mortality in hypertensive adults across the glycemic continuum: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Relationship between triglyceride-glucose-derived obesity indices and NAFLD in adolescents: A cross-sectional study.Medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInsulin resistance (IR) serves as a core pathophysiological factor among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and has an adverse impact on prognosis. As a reliable indicator of IR, the estimated glucose disposal rate (eGDR) is associated with cardiometabolic risk and mortality. However, the prognostic significance of eGDR in MASLD remains unclear. This study aims to examine the association between eGDR and cause-specific mortality in patients with MASLD.
methodsTotally 6,847 patients with MASLD were included from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. Patients were divided into four groups based on eGDR quartiles. The study outcomes were all-cause, cardiovascular and diabetes mortality. Restricted cubic splines (RCS) and the Cox proportional hazard model were used to evaluate the associations between eGDR and outcomes. Receiver operating characteristic (ROC) analyses were conducted to show its predictive ability for outcomes. Subgroup analyses were conducted to evaluate the robustness of performance.
resultsDuring the median follow-up of 8.8 years, 19.6% patients (n = 1,345) experienced death, with 6.5% (n = 443) cardiovascular mortality, and 1.3% (n = 89) diabetes mortality. After adjusting for confounders, higher eGDR level was significantly associated with lower risk of all-cause mortality (HR = 0.94, 95% CI: 0.92-0.97, P < 0.001), cardiovascular mortality (HR = 0.90, 95% CI:0.85-0.95, P < 0.001), and diabetes mortality (HR = 0.70, 95% CI: 0.62-0.80, P < 0.001). ROC analyses showed that the eGDR had a significant but modest predictive performance for all-cause mortality (AUC = 0.606) and cardiovascular mortality (AUC = 0.631), with a moderate performance for diabetes mortality (AUC = 0.729). Among different subgroups, the association between the eGDR and the risk of cause-specific mortality was similar to the main results.
conclusionHigher eGDR levels are independently associated with reduced risks of all-cause, cardiovascular, and diabetes mortality among patients with MASLD, highlighting the prognostic relevance of insulin resistance in this population. The modest discriminative performance of eGDR further supports its role in cardiometabolic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.